Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing
(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also Read More